Jung-Ryul Kim
Overview
Explore the profile of Jung-Ryul Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kim K, Lee D, Shin Y, Kang S, Kim J, et al.
Sensors (Basel)
. 2021 Sep;
21(18).
PMID: 34577462
We herein report a simultaneous frequency stabilization of two 780-nm external cavity diode lasers using a precision wavelength meter (WLM). The laser lock performance is characterized by the Allan deviation...
2.
Jang H, Lee K, Jeon J, Kim J, Lee J, Kwon G, et al.
Front Immunol
. 2020 Nov;
11:564288.
PMID: 33178190
Intrarenal robust inflammatory response following ischemia-reperfusion injury (IRI) is a major factor in the pathogenesis of renal injury in ischemic acute kidney injury (AKI). Although numerous studies have investigated various...
3.
Park J, Kim J
Transl Clin Pharmacol
. 2020 Feb;
27(3):89-91.
PMID: 32055588
MATLAB® is widely used for numerical analysis, modeling, and simulation. One of MATLAB's tools, SimBiology®, is often used for pharmacokinetic, pharmacodynamic model and dynamic systems; however, SimBiology seems to be...
4.
Shin D, Shin D, Kim J
J Stroke Cerebrovasc Dis
. 2019 Dec;
29(2):104516.
PMID: 31791651
Background And Purpose: ASPECTS (Alberta Stroke Program Early CT Score) is a 10-point topographic CT scan score that has been shown to be a strong prognostic factor in acute ischemic...
5.
Kim S, Lee H, Ko J, Kim J
Clin Ther
. 2019 Oct;
41(11):2204-2218.
PMID: 31564512
Purpose: Celecoxib is a selective cyclooxygenase-2 inhibitor widely used in patients with osteoarthritis and rheumatoid arthritis. Recently, nonclinical data on the inhibition of human ether-à-go-go-related gene potassium channels by celecoxib...
6.
Kim S, Ko J, Kim J
Clin Pharmacol Drug Dev
. 2019 Aug;
9(3):386-394.
PMID: 31373174
The objective of study was to compare the pharmacokinetic and safety profiles of a fixed-dose combination (FDC) formulation of 5/160/20 mg amlodipine/valsartan/atorvastatin with those of separate formulations of a 5/160-mg...
7.
Kim J, Jung J, Kim S, Huh W, Ghim J, Shin J, et al.
Biomed Res Int
. 2019 Feb;
2019:1365180.
PMID: 30729119
Purpose: We evaluated potential drug-drug interactions between cilostazol and simvastatin, both CYP3A substrates, in healthy subjects. Methods: An open-label, two-period, fixed-sequence clinical study was conducted. Seventeen subjects were given a...
8.
Cho H, Seo J, Lee H, Kim S, Kang K, Kim J, et al.
BMC Musculoskelet Disord
. 2019 Jan;
20(1):3.
PMID: 30611249
Background: The gluteus medius muscle plays a very important role in the stability of the gait, especially in patients with amputation of the lower limbs. Therefore, choosing the appropriate type...
9.
Kim S, Hong T, Ko J, Huh W, Kim J
BioDrugs
. 2018 Dec;
33(1):101-112.
PMID: 30506495
Objective: This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and safety properties of the test (CJ-40001) and reference (NESP) versions of darbepoetin alfa following a single subcutaneous (SC) or intravenous...
10.
Kim J, Kim S, Huh W, Ko J
Drug Des Devel Ther
. 2018 Aug;
12:2475-2483.
PMID: 30127595
Purpose: To evaluate the pharmacokinetics and pharmacodynamics of candesartan and amlodipine in the absence and presence of each other in healthy subjects. Methods: This study consisted of two parts: part...